Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Boehringer Ingelheim
AstraZeneca
Johnson and Johnson
Baxter

Last Updated: September 25, 2022

XIMINO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Ximino patents expire, and what generic alternatives are available?

Ximino is a drug marketed by Journey and is included in one NDA. There are six patents protecting this drug.

This drug has thirteen patent family members in ten countries.

The generic ingredient in XIMINO is minocycline hydrochloride. There are fifteen drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.

US Patents and Regulatory Information for XIMINO

XIMINO is protected by six US patents.

Patents protecting XIMINO

Minocycline oral dosage forms for the treatment of acne
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS

Minocycline oral dosage forms for the treatment of acne
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Minocycline oral dosage forms for the treatment of acne
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ACNE

Method for the treatment of acne
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ACNE

Minocycline oral dosage forms for the treatment of acne
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ACNE

Minocycline oral dosage forms for the treatment of acne
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ACNE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Journey XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012 RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Journey XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-005 Jul 11, 2012 RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Journey XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-002 Jul 11, 2012 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Journey XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012 RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Journey XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-003 Jul 11, 2012 RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Journey XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-005 Jul 11, 2012 RX No No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Journey XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-003 Jul 11, 2012 RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for XIMINO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Journey XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012 See Plans and Pricing See Plans and Pricing
Journey XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-005 Jul 11, 2012 See Plans and Pricing See Plans and Pricing
Journey XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-003 Jul 11, 2012 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for XIMINO

See the table below for patents covering XIMINO around the world.

Country Patent Number Title Estimated Expiration
Japan 2008543936 See Plans and Pricing
Norway 20080444 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2007001961 See Plans and Pricing
New Zealand 564093 Method for the treatment of acne using an oral minocycline antibiotic See Plans and Pricing
South Africa 200802064 Method for the treatment of acne See Plans and Pricing
Japan 2013213047 METHOD FOR TREATMENT OF ACNE See Plans and Pricing
Japan 5744976 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
McKinsey
Baxter
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.